| __timestamp | Supernus Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 72471000 | 59644696 |
| Thursday, January 1, 2015 | 89204000 | 79541000 |
| Friday, January 1, 2016 | 106010000 | 98015000 |
| Sunday, January 1, 2017 | 137905000 | 103958000 |
| Monday, January 1, 2018 | 159888000 | 103654000 |
| Tuesday, January 1, 2019 | 158425000 | 128951000 |
| Wednesday, January 1, 2020 | 200677000 | 135799000 |
| Friday, January 1, 2021 | 304759000 | 149883000 |
| Saturday, January 1, 2022 | 377221000 | 220206000 |
| Sunday, January 1, 2023 | 336361000 | 265542000 |
Unleashing the power of data
In the ever-evolving landscape of biopharmaceuticals, operational efficiency is paramount. Over the past decade, Supernus Pharmaceuticals, Inc. and Travere Therapeutics, Inc. have demonstrated distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Supernus Pharmaceuticals saw a staggering 364% increase in SG&A expenses, peaking in 2022. This reflects their aggressive expansion and strategic investments. In contrast, Travere Therapeutics experienced a 345% rise, with a notable surge in 2023, indicating a strategic pivot towards growth.
These trends underscore the companies' differing strategies: Supernus's focus on scaling operations and Travere's recent emphasis on market penetration. As the biopharma sector continues to innovate, understanding these financial dynamics offers valuable insights into future industry directions.
Novo Nordisk A/S and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Supernus Pharmaceuticals, Inc.
Zoetis Inc. vs Travere Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Summit Therapeutics Inc. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Insmed Incorporated or Travere Therapeutics, Inc.
Blueprint Medicines Corporation vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Apellis Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Supernus Pharmaceuticals, Inc. and MannKind Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Travere Therapeutics, Inc. or Novavax, Inc.